| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
2,170,000 |
| Market
Cap: |
1.75(M) |
| Last
Volume: |
881,740 |
Avg
Vol: |
301,084 |
| 52
Week Range: |
$0.62 - $10.9 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical company developing an oral small molecule ribosome modulating agents and eukaryotic ribosome selective glycosides (ERSGs) for the treatment of rare and ultra-rare premature stop codon diseases and ribosomal mutations. Co.'s TURBO-ZM™ platform is designed to enable synthesis of macrolides that can be supported to modulate the human, bacterial or viral ribosomes to treat rare diseases. ELX-02, an ERSG, is a small molecule drug candidate designed as an analogue to gentamicin and geneticin to restore production of functional proteins, and is in clinical development for the treatment of cystic fibrosis patients with nonsense mutations.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Shabtai Gilad |
10% Owner |
– – • |
2018-03-29 |
4 |
B |
$9.64 |
$43,380 |
D/D |
4,500 |
3,268,470 |
2.37 |
- |
|
| Avnur Zafrira |
Director |
– • – |
2018-03-26 |
4 |
B |
$9.49 |
$18,980 |
I/I |
2,000 |
2,263 |
2.1 |
- |
|
| Ward Robert |
Chief Executive Officer |
• • – |
2018-03-23 |
4 |
B |
$8.99 |
$89,900 |
D/D |
10,000 |
10,000 |
2.81 |
- |
|
| Weaver Gregory L |
Chief Financial Officer |
• – – |
2018-03-23 |
4 |
B |
$8.56 |
$38,520 |
D/D |
4,500 |
4,500 |
2.74 |
- |
|
| Pontifax Iv Gp L.p. |
10% Owner |
– – • |
2018-03-22 |
4 |
B |
$8.00 |
$48,000 |
I/I |
6,000 |
427,063 |
1.5 |
- |
|
| Nussbaum Ran |
Director |
– • – |
2018-03-22 |
4 |
B |
$8.00 |
$48,000 |
I/I |
6,000 |
427,063 |
2.1 |
- |
|
| Kariv Tomer |
Director |
– • – |
2018-03-22 |
4 |
B |
$8.00 |
$48,000 |
I/I |
6,000 |
427,063 |
2.1 |
- |
|
| Pontifax Iv Gp L.p. |
10% Owner |
– – • |
2018-03-21 |
4 |
B |
$7.55 |
$49,830 |
I/I |
6,600 |
425,463 |
1.5 |
- |
|
| Nussbaum Ran |
Director |
– • – |
2018-03-21 |
4 |
B |
$7.55 |
$49,830 |
I/I |
6,600 |
425,463 |
2.1 |
- |
|
| Kariv Tomer |
Director |
– • – |
2018-03-21 |
4 |
B |
$7.55 |
$49,830 |
I/I |
6,600 |
425,463 |
2.1 |
- |
|
| Avnur Zafrira |
Director |
– • – |
2018-03-21 |
4 |
B |
$7.60 |
$1,999 |
I/I |
263 |
263 |
2.02 |
- |
|
| Opko Health, Inc. |
10% Owner |
– – • |
2017-12-19 |
4 |
A |
$0.00 |
$0 |
D/D |
495,126 |
1,289,818 |
|
- |
|
| Opko Health, Inc. |
10% Owner |
– – • |
2017-09-19 |
4 |
A |
$0.00 |
$0 |
D/D |
1,250,006 |
15,893,844 |
|
- |
|
| Opko Health, Inc. |
10% Owner |
– – • |
2017-08-10 |
4 |
OE |
$0.10 |
$412,682 |
D/D |
4,126,822 |
14,643,838 |
|
- |
|
| Opko Health, Inc. |
10% Owner |
– – • |
2017-07-28 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
10,517,016 |
|
- |
|
| Frost Gamma Investment Trust |
10% Owner |
– – • |
2015-09-29 |
4 |
B |
$0.61 |
$21,350 |
I/I |
35,000 |
1,598,170 |
1.5 |
- |
|
| Graziano James Joseph |
Chief Technology Officer |
• – – |
2014-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
104,386 |
104,386 |
|
- |
|
| Frost Gamma Investment Trust |
Director |
– • • |
2014-05-16 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
666,666 |
|
- |
|
| Smider Vaughn |
Chief Scientific Officer |
• • – |
2014-05-16 |
4 |
A |
$0.00 |
$0 |
I/I |
31,396 |
1,058,970 |
|
- |
|
| Smider Vaughn |
Chief Scientific Officer |
• • – |
2014-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
1,027,574 |
1,058,970 |
|
- |
|
| Frost Gamma Investment Trust |
Director |
– • • |
2014-05-16 |
4 |
A |
$0.00 |
$0 |
I/I |
896,504 |
1,563,170 |
|
- |
|
| Quick Thomas C |
Director |
– • – |
2014-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
13,149 |
|
- |
|
| Isabelle Warren John |
Director |
– • – |
2014-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
6,038 |
|
- |
|
98 Records found
|
|
Page 4 of 4 |
|
|
0.02 (2.65%) 
